Watson to meet with FDA in February to discuss GMP warning letter.
Executive Summary
WATSON RECURRENT GMP DEFICIENCIES CITED BY FDA in Jan. 28 warning letter regarding good manufacturing practices observations made during a Nov. 13-21 inspection of the firm's Corona, Calif. facility. FDA "has significant concerns about the corrective measures undertaken by your company to eliminate the recurrence of the deficiencies disclosed in earlier inspections conducted by our office," the warning letter states.